rs854555 — PON1 PON1 3'UTR variant

PON1 3'UTR Variant — A Haplotype Tag for HDL Antioxidant Capacity

Paraoxonase-1 (PON1) is a calcium-dependent enzyme bound exclusively to HDL particles¹¹ HDL particles
High-density lipoprotein, the "good cholesterol" that transports cholesterol from tissues back to the liver and carries anti-atherogenic enzymes in the bloodstream. Its primary cardiovascular role is preventing LDL from oxidizing — the crucial first step in atherosclerotic plaque formation. rs854555 is an intronic variant within PON1 at chromosome 7q21.3 that does not change the protein sequence itself, but travels in linkage disequilibrium with functional PON1 variants. It is a haplotype tag²² haplotype tag
A variant whose allele can be used to infer the genotype of nearby variants in strong LD, acting as a proxy for a cluster of co-inherited alleles for a low-activity PON1 haplotype, meaning carriers of the A allele tend to have lower overall PON1 enzymatic activity on their HDL particles.

The Mechanism

PON1 activity in plasma is determined by two independent factors: how much enzyme the liver produces (controlled by promoter variants such as rs854571 at −108C>T) and how efficiently the available enzyme works (controlled by coding variants such as rs662 Q192R and rs854560 L55M). rs854555, lying within an intron, does not directly alter transcription or protein function. Instead, its alleles are inherited together with combinations of functional variants — the A allele co-segregating preferentially with low-activity haplotype configurations across diverse populations.

The consequence of reduced PON1 loading on HDL is a decrease in the enzyme's capacity to hydrolyze lipid peroxides accumulating on LDL and HDL particles. When PON1 activity falls, oxidized LDL — the key driver of foam cell formation³³ foam cell formation
Macrophages engulf oxidized LDL to form foam cells, the cellular building blocks of atherosclerotic plaques and arterial plaque — accumulates unchecked. The GWAS Catalog records a genome-wide significant association between rs854555-A and altered response to TNF antagonist therapy (p = 2 × 10⁻⁶), consistent with PON1's documented role in modulating inflammatory signaling via oxidized phospholipid hydrolysis.

The Evidence

Direct evidence for rs854555 as an independent risk variant is limited; its importance lies in haplotype context. A 2017 case-control study in Han Chinese found that the A-A haplotype at rs854555 and rs662⁴⁴ A-A haplotype at rs854555 and rs662
Li et al. Medicine (Baltimore) 2017 (combining the rs854555 A allele with the rs662 Q variant) was significantly associated with increased disease susceptibility (OR 2.74, 95% CI 1.28–5.84), while rs854555 alone showed no independent effect — the hallmark of a haplotype-tagging variant.

The pathway consequence is well-established even where this specific SNP's independent contribution is modest. A meta-analysis of 43 studies comprising 20,629 subjects⁵⁵ 43 studies comprising 20,629 subjects
Zhao et al. Mol Genet Metab 2012 found that reduced PON1 activity is a significant risk factor for coronary heart disease (SMD −0.78, 95% CI −0.98 to −0.57, P<0.001 for paraoxonase activity; SMD −0.50 for arylesterase activity). A second meta-analysis of 20 studies (n=5,417)⁶⁶ 20 studies (n=5,417)
Zuin et al. Dis Markers 2022 confirmed that PON1 arylesterase activity is significantly lower in CAD patients versus controls (SMD −0.587, P<0.0001). Carriers of the rs854555 A allele, by co-inheriting low-activity haplotype configurations, participate in this pathway.

Practical Actions

The most evidence-supported strategy for individuals with low-activity PON1 haplotypes is increasing dietary polyphenol intake. Pomegranate juice consumption for 12 months increased serum PON1 activity by 83% in a controlled study⁷⁷ 83% in a controlled study
Aviram et al. Clin Nutr 2004 of carotid artery stenosis patients, while simultaneously reducing LDL basal oxidative state by 90%. Extra virgin olive oil — through its oleic acid content and minor phenolic compounds — has been shown in multiple trials to upregulate hepatic PON1 mRNA expression and directly stimulate arylesterase activity on HDL particles.

Because rs854555 is a haplotype tag rather than a functional variant, its predictive value is strengthened when interpreted alongside the coding and promoter PON1 variants (rs662, rs854560, rs854571). Individuals with the A allele at rs854555 combined with unfavorable genotypes at those functional sites carry the most reduced total PON1 activity. Direct measurement of serum PON1 arylesterase activity provides a functional readout that integrates all genetic and non-genetic determinants.

Interactions

rs854555 sits within a well-characterized PON1 haplotype structure. Its A allele tends to co-inherit with configurations that reduce functional PON1 enzyme delivery to HDL. The three key functional sites are: rs662 (Q192R)⁸⁸ rs662 (Q192R)
Amino acid substitution that trades LDL antioxidant efficiency for organophosphate hydrolysis speed; the 192R allele is associated with higher CAD risk in multiple meta-analyses, rs854560 (L55M, which reduces PON1 protein stability and serum concentration by >50%), and rs854571 (−108C>T promoter, which controls total transcriptional output of the gene). The combined genotype across all four sites determines an individual's effective PON1 activity far more precisely than any single variant alone.